Related Experiment Video

Updated: Jun 11, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Three common CARD15 mutations are not responsible for the pathogenesis of Crohn's disease in Iranians

Ladan Teimoori-Toolabi1, Homayoun Vahedi, Hamid Mollahajian

  • 1Digestive Disease Research Center (DDRC), Shariati Hospital, Tehran University, Medical Sciences North Kargar Street, Tehran, Iran 14117-13135. liosha1380@yahoo.com

Hepato-Gastroenterology
|June 30, 2010
PubMed

Insights

Common Caspase Recruitment Domain 15 (CARD15) gene mutations are not prevalent in Iranian Crohn's Disease patients. This study found the R702W mutation in only two patients, suggesting it is not a major factor in the disease's development in this population.

Area of Science:

  • Genetics
  • Gastroenterology
  • Molecular Biology

Background:

  • Crohn's disease incidence is rising in Iran.
  • Caspase Recruitment Domain 15 (CARD15) gene mutations are known genetic risk factors for Crohn's disease.
  • Previous studies have investigated CARD15 mutation frequencies in various ethnic groups.

Purpose of the Study:

  • To determine the frequency of three common CARD15 mutations (Lf1007fs, R702W, G908R) in Iranian Crohn's disease patients.
  • To assess the role of these specific CARD15 mutations in the pathogenesis of Crohn's disease within the Iranian population.

Main Methods:

  • A case-control study involving 115 Crohn's disease patients and 115 healthy controls.
  • Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was used to detect Lf1007fs, R702W, and G908R mutations.
  • Positive cases identified by PCR-RFLP were further confirmed by sequencing.

Main Results:

  • Lf1007fs and G908R mutations were absent in both patients and controls.
  • The R702W mutation was detected in only two Crohn's disease patients.
  • These two patients with the R702W mutation did not exhibit ileal or fibrostenotic disease and had no acquired complications.

Conclusions:

  • The studied CARD15 mutations (Lf1007fs, R702W, G908R) do not appear to be significant contributors to Crohn's disease pathogenesis in Iranians.
  • These findings align with previous research on inflammatory bowel disease (IBD) patients in other Asian countries.
  • Further research may be needed to identify other genetic or environmental factors influencing Crohn's disease in Iran.
Abstract

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...